Graft-Versus-Host Disease (GVHD) Clinical Trials

A listing of Graft-Versus-Host Disease (GVHD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 240 clinical trials
High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant

This phase I trial studies the side effects and how well high dose vitamin A works in preventing gastrointestinal graft versus host disease (GVHD) in participants undergoing donor stem cell

  • 1 views
  • 07 Mar, 2021
  • 1 location
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids

  • 0 views
  • 25 Mar, 2021
  • 1 location
Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear. The aim of this randomised

acute graft-versus-host disease
granulocyte colony stimulating factor
bone marrow transplant
anemia
filgrastim
  • 47 views
  • 07 Nov, 2020
  • 1 location
Vigamox Treatment for Ocular Graft-Versus-Host Disease

In this study the investigators seek to prospectively measure the response of ocular graft-versus-host disease (GVHD) patients to treatment with topical Vigamox. The investigators will

  • 0 views
  • 03 Feb, 2021
  • 1 location
A Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplant in Patients With Fanconi Anemia.

patients, due to complications with their condition, may have a high risk of acquiring possibly life-threatening treatment-related side effects such as graft versus host disease (GVHD

graft versus host disease
campath
fludarabine
anemia
  • 34 views
  • 07 Nov, 2020
  • 1 location
Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

more effective in preventing graft versus host disease (GVHD) and rejection of organ transplants. As the fludarabine based conditioning regimens without total body irradiation have been

graft versus host disease
antithymocyte globulin
severe aplastic anemia
neutrophil count
cell transplantation
  • 29 views
  • 07 Nov, 2020
  • 1 location
Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease

condition called ‘graft versus host disease’ (GVHD). In this condition the transplanted cells recognize the recipient as foreign and bring about an immune-mediated destruction of tissues. The

immunosuppression
immunosuppressive agents
blood stem cell transplant
acute graft-versus-host disease
  • 16 views
  • 07 Nov, 2020
  • 1 location
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

cells as the CIML NK cells are derived from the same donor. The use of CIML NK cells is unlikely to lead to excessive graft versus host disease (GVHD) as previous studies have not been associated with

  • 24 views
  • 26 Sep, 2021
  • 1 location
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

transplantation for adults is still being explored. The application of cord blood in supportive treatment can be actively explored. Cord blood has low immunogenicity and is unlikely to cause Graft versus host

  • 0 views
  • 01 Sep, 2021
  • 2 locations
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

3-5 years following allo-HCT. This is due to non-relapse mortality, which is significantly associated with the development of graft-versus-host disease (GVHD), but also due to disease

richter syndrome
ofatumumab
chronic lymphocytic leukemia
bendamustine
cancer
  • 12 views
  • 08 Nov, 2020
  • 2 locations